캐드레날 테라퓨틱스(CVKD)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.87 (+0.54%), 시가총액 $0.02B, 52주 범위 $4.25 ~ $15.70.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a pare
캐드레날 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
캐드레날 테라퓨틱스의 현재 주가는 $1.87 (+0.54%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
캐드레날 테라퓨틱스의 시가총액은 약 $0.02B입니다.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin